MedTrace Logo

Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis

NCT03011281 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 378

Last updated 2020-06-25

No results posted yet for this study

Summary

The objectives of this single center, prospective, non-interventional inception cohort is to understand patient characteristics, general treatment patterns, effectiveness, and safety of Tofacitinib for rheumatoid arthritis patients in the real-world setting.

1. To evaluate the baseline characteristics of Korean RA patients treated with Tofacitinib
2. To evaluate the effectiveness and safety of Tofacitinib in clinical practice in Korean RA patients.
3. To further evaluate safety, effectiveness and demographic characteristics of the patients treated with Tofacitinib matched with and compared to biologic DMARDs from the BIOPSY registry database.

Conditions

Interventions

DRUG

Tofacitinib

Sponsors & Collaborators

  • Hanyang University

    lead OTHER

Principal Investigators

  • Yoon-Kyoung Sung, MD, PhD, MPH · Hanyang University Hospital for Rheumatic Diseases

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011281 on ClinicalTrials.gov